Are Contemporary Antifungal Doses Sufficient for Critically Ill Patients? Outcomes from an International, Multicenter Pharmacokinetics Study for Screening Antifungal Exposure in Intensive Care Units—The SAFE-ICU Study

Medicine, Infectious Diseases, Pharmacy,
antifungals   pharmacokinetics   intensive care unit   invasive fungal disease   dose optimization  

International Multicenter Study Reveals Insufficient Antifungal Dosing in Critically Ill Patients Academic Background Invasive fungal infections are common and serious nosocomial infections, particularly among patients in the intensive care unit (ICU), where they are associated with high morbidity and mortality rates. Timely and appropriate antifun...

In Vivo Brain Delivery of BBB-Enabled Iduronate 2-Sulfatase in Rats

Medicine, Neurology, Life Sciences, Biochemistry,
blood brain barrier   MPS II   iduronate-2-sulfatase   enzyme replacement therapy   CSF   brain   pharmacokinetics  

Delivery of Enzyme Replacement Therapy Across the Blood-Brain Barrier for Hunter Syndrome Background Hunter syndrome (Mucopolysaccharidosis II, MPS II) is a rare inherited metabolic disorder caused by a deficiency of the iduronate-2-sulfatase (IDS) enzyme. This enzyme deficiency leads to the accumulation of glycosaminoglycans (such as heparan sulfa...

Reduced Oxycodone Brain Delivery in Rats due to Lipopolysaccharide-Induced Inflammation: Microdialysis Insights into Brain Disposition and Sex-Specific Pharmacokinetics

Medicine, Anesthesiology, Pharmacy,
blood-brain barrier   oxycodone   microdialysis   sex-specific   lipopolysaccharides   inflammation   pharmacokinetics  

The Impact of Inflammation on Brain Delivery of Oxycodone Academic Background Oxycodone is a widely used opioid analgesic with a unique property of being actively transported from the blood to the brain across the blood-brain barrier (BBB). This process is believed to be associated with the proton-coupled organic cation (H+/OC) antiporter system. H...